The accelerated approval was based on results from the Phase I/II SOHO-01 trial showing a 75 percent response rate to ...
The FDA has granted priority review to Intellia’s biologics license application for lonvo-z and plans to issue a decision by March 10, 2027.
The firm plans to study the PI3K/AKT/mTOR inhibitor paxalisib in combination with Merck's Keytruda in microsatellite stable and proficient mismatch repair colorectal cancer.
NEW YORK – New research suggests that molecular aging can vary considerably between individuals depending on their genetics and environmental exposures as well as the season and their circadian rhythm ...
The Fitrapid test is a noninvasive at-home kit designed to detect fecal occult blood, an early warning sign of lower gastrointestinal tract diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results